AIM ImmunoTech Inc. (AIMID)
OTCMKTS · Delayed Price · Currency is USD
6.70
-1.68 (-20.05%)
At close: Jun 13, 2025

AIM ImmunoTech Company Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.

Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.

The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.

The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.

AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc.
Country United States
Founded 1966
Industry Biological Products, Except Diagnostic Substances
Employees 23
CEO Thomas Equels

Contact Details

Address:
2117 SW Highway 484
Ocala, Delaware 34473
United States
Phone 352 448 7797
Website aimimmuno.com

Stock Details

Ticker Symbol AIMID
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Thomas Equels Chief Executive Officer
Robert Dickey Chief Financial Officer
Peter Rodino Chief Operating Officer
Ann Marie Coverly Head of Investor Relations